© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
Author | Jason M. Broderick
Articles
Ide-cel Appears Active in Almost Three-Fourths of Heavily Pretreated Patients with Myeloma
June 06, 2020
ByJason M. BroderickThe BCMA-targeting CAR T-cell therapy yielded a response in73% of patients with heavily pretreated relapsed/refractory multiple myeloma.